FAAH Enzyme

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Plain-language summary

FAAH (fatty acid amide hydrolase) is an enzyme embedded in cell membranes throughout your body, especially in the brain and liver. Its main job is to break down anandamide — a signaling molecule your body makes naturally that binds the same CB1 receptor as THC Strong evidence ^[1]. When FAAH works normally, anandamide signals briefly and then gets degraded. When FAAH is blocked or genetically less active, anandamide accumulates, and CB1 signaling intensifies — without the person ever using cannabis.

This made FAAH a major drug-development target in the 2000s and 2010s. The promise: inhibit FAAH, get cannabis-like benefits (pain relief, reduced anxiety) without intoxication, because you're only boosting endocannabinoids already made by your body. Two decades later, that promise has largely not materialized clinically. No FAAH inhibitor is approved for any medical indication anywhere in the world.

This article is not medical advice. It summarizes what published evidence does and does not show. If you are considering any cannabinoid-related therapy, consult a clinician.

What FAAH is and how it works

FAAH is a serine hydrolase — it uses a serine amino acid residue to cleave amide bonds. Its primary substrate is anandamide (N-arachidonoylethanolamine, AEA) Strong evidence ^[1]. It also breaks down related lipids: oleoylethanolamide (OEA), involved in appetite and satiety; palmitoylethanolamide (PEA), involved in inflammation; and other N-acylethanolamines ^[2].

When the FAAH gene is knocked out in mice, anandamide levels rise 10–15-fold in the brain, and the animals show reduced pain responses and reduced anxiety-like behavior in standard laboratory assays Strong evidence ^[3]. Importantly, this phenotype is achieved without administering any exogenous drug.

In humans, a common genetic variant — C385A (rs324420) — produces a less stable FAAH protein, leading to modestly higher baseline anandamide levels in people carrying it Weak / limited ^[4]. This variant has been linked observationally to lower anxiety and enhanced fear extinction in learning tasks, though effect sizes are small and replication across studies is inconsistent Weak / limited ^[5].

The most famous natural human case is Jo Cameron, a Scottish woman who experiences almost no pain or anxiety. She carries a microdeletion in FAAH-OUT, a pseudogene that negatively regulates FAAH expression, resulting in very low FAAH activity and elevated anandamide levels Strong evidence ^[6]. As far as published records show, she is essentially unique.

What probably works

The solid, replicated finding is pharmacological: FAAH inhibitors do raise anandamide levels in human plasma, confirmed by direct measurement in Phase 1 clinical trials Strong evidence ^[7]. The mechanism is real. Translating that into clinical benefit is where the approach has stalled.

In rodent models, FAAH inhibition robustly reduces pain in inflammatory and neuropathic assays and reduces anxiety-like behavior Strong evidence ^[3]. That animal-model signal motivated billions of dollars in investment from major pharmaceutical companies.

However, efficacy in rodents has not translated reliably to humans. No FAAH inhibitor has progressed from Phase 2 or Phase 3 trials to regulatory approval anywhere, and several compounds have been discontinued after early-stage trials.

What might work (weak evidence)

Anxiety disorders. A Phase 2 randomized controlled trial of the FAAH inhibitor JNJ-42165279 in social anxiety disorder reported a modest reduction in symptom severity versus placebo Weak / limited ^[8]. This was one trial with modest effect size and has not been replicated or advanced to regulatory review.

Cannabis use disorder and withdrawal. A Phase 2a trial of PF-04457845 in men with cannabis dependence found reduced withdrawal symptoms and lower cannabis use during a 4-week treatment window Weak / limited ^[9]. The trial was single-site with a small sample and did not progress to Phase 3 or approval.

PTSD and fear extinction. Carriers of the FAAH C385A variant show enhanced fear extinction in controlled laboratory paradigms Weak / limited ^[5]. A small study found PF-04457845 enhanced recall of fear extinction in healthy volunteers Weak / limited ^[10]. Neither finding has led to an approved treatment.

Chronic pain. Despite decades of preclinical promise, FAAH inhibitors have repeatedly failed in human pain trials. Pfizer's PF-04457845 did not separate from placebo for osteoarthritis pain in a Phase 2 trial Strong evidence ^[11]. Multiple other compounds have been abandoned after similarly negative results.

What does not work or lacks evidence

• FAAH inhibitors for human chronic pain. Multiple Phase 2 trials have shown no benefit over placebo, despite strong efficacy in rodent pain models Strong evidence ^[11]. This remains the largest failure of FAAH inhibition as a therapeutic strategy.

• Over-the-counter 'FAAH inhibitor' supplements. Foods and supplements marketed as FAAH-inhibiting (dark chocolate, kava, certain herbs) contain compounds that inhibit FAAH in vitro (in test tubes) at concentrations orders of magnitude higher than achievable from diet or supplements No data. No credible evidence shows that any commercially marketed supplement meaningfully raises anandamide in living humans.

• Cannabis as a FAAH inhibitor. THC binds CB1 receptors directly as an agonist; it is not a meaningful inhibitor of FAAH. CBD has weak FAAH-inhibitory activity in some cell assays, but human relevance is unclear and disputed Disputed ^[12].

• The C385A variant as a predictor of individual cannabis response. Some consumer genetics companies have marketed this variant as predictive of cannabis sensitivity. Effect sizes are too small and clinically uninformative for individual decision-making Weak / limited.

What we don't know

• Species translation failure. Why FAAH inhibition works so reliably in rodent models but has repeatedly failed in humans for pain and anxiety. Leading hypotheses include fundamental differences in endocannabinoid tone between species, compensatory upregulation of other anandamide-degrading enzymes (MAGL, NAAA), wrong patient populations being enrolled, and uncharacterized genetic or neurobiological differences.

• Dual-target and peripherally-restricted compounds. Whether FAAH inhibitors combined with MAGL inhibitors, or compounds that do not penetrate the blood-brain barrier, might have better clinical outcomes. Some are in early development, but no robust human data exist.

• Long-term safety of chronically elevated anandamide. Decades of data exist on chronic THC exposure, but very little on the long-term safety of sustained elevation of endogenous CB1 signaling in humans via FAAH inhibition. Theoretical concerns include metabolic effects, cognitive changes, and mood dysregulation.

• Whether the Jo Cameron phenotype can be safely mimicked pharmacologically. She is a single individual with a unique genetic microdeletion. Whether her pain insensitivity and anxiety resilience can be replicated in the general population via pharmacology remains unknown and may not be feasible.

Comparison with standard treatments

For chronic pain: Standard-of-care treatments (nonsteroidal anti-inflammatory drugs, duloxetine, gabapentinoids, and physical therapy; opioids in select cases) have decades of randomized controlled trial evidence and are FDA-approved. FAAH inhibitors have failed to beat placebo in head-to-head and placebo-controlled trials ^[11]. They are not a viable clinical option.

For anxiety disorders: SSRIs and SNRIs are first-line, have robust long-term efficacy data, and are approved by the FDA. FAAH inhibitors have one Phase 2 trial showing modest benefit ^[8]. There is no meaningful comparison; established treatments are far better supported.

For cannabis use disorder: There are no FDA-approved pharmacotherapies. FAAH inhibition is one of several investigational approaches, alongside gabapentin, N-acetylcysteine, and CBD, none of which are standard-of-care ^[9]. Cognitive-behavioral therapy remains the best-supported intervention.

Compared to cannabis itself: A FAAH inhibitor would in theory raise only endogenous anandamide rather than exogenously flood CB1 with THC and other phytocannabinoids. In practice, since no FAAH inhibitor is approved, this remains a theoretical comparison.

Risks: the BIA 10-2474 disaster and known adverse effects

In January 2016, a Phase 1 trial in Rennes, France, of the FAAH inhibitor BIA 10-2474 (developed by Bial, a Portuguese company) caused the death of one healthy volunteer and severe neurological injury in four others Strong evidence ^[13][14]. Investigation by independent researchers concluded that toxicity was likely due to off-target binding of that specific compound — it inhibited several lipase enzymes beyond FAAH at high doses — rather than inherent danger of FAAH inhibition itself ^[14]. More selective, later-generation compounds like PF-04457845 did not cause similar severe toxicity in clinical trials.

Nonetheless, the BIA 10-2474 event is a permanent reminder that targeting the endocannabinoid system is not automatically "safe" and that drug selectivity is critical.

Known or theoretical adverse effects of FAAH inhibition include:

• Drowsiness, headache, dizziness (reported across early trials)
• Theoretical metabolic effects, including weight gain (FAAH also degrades OEA, a satiety signal)
• Theoretical cognitive or mood effects from sustained CB1 over-activation
• Unknown long-term safety profile in chronic use

Again: this is not medical advice. If you are considering any endocannabinoid-targeted therapy, consult a physician familiar with this area of medicine.

Sources

How this page was made

Related

• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
• CBD and Anxiety — Strong evidence for one-time high-dose CBD before acute stressors; weak evidence for daily...
• FAAH Inhibitors — Drugs that block anandamide breakdown, not terpenes or cannabinoids.